GW Pharmaceuticals Investors Sue To Stop $7.2B Acquisition

GW Pharmaceuticals Investors Sue To Stop $7.2B Acquisition Two shareholders in cannabinoid drugmaker GW Pharmaceuticals are suing to stop its planned $7.2 billion acquisition by another pharmaceutical company, saying the deal was the result of an unfair and misleading process that undercuts investors and benefits insiders. #CBD #Hemp https://www.law360.com/cannabis/articles/1366153?utm_source=rss&utm_medium=rss&utm_campaign=section March 18, 2021 9:21 pm